risedronic acid has been researched along with Dyslipidemias in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse event incidence was marginally higher in DL compared with non-DL (Relative risk 1." | 2.82 | Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan. ( Inoue, D; Muraoka, R; Nishizawa, Y; Okazaki, R; Sugimoto, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, D | 1 |
| Muraoka, R | 1 |
| Okazaki, R | 1 |
| Nishizawa, Y | 1 |
| Sugimoto, T | 1 |
1 trial available for risedronic acid and Dyslipidemias
| Article | Year |
|---|---|
Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Comorbidity; Diabetes Mellitus; Double- | 2016 |